ERBB2 and colorectal carcinoma: Although ERBB2-targeted agents are not routinely administered to patients with mCRC who test positive for the protein, ERBB2 plays a significant role in CRC; it may therefore be a predictor of success for innovative targeted therapies in the age of precision medicine and in the context of genetic heterogeneity [16].